1. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma 
Jennifer A.Vanden Burgt, BSa, William W. Busse, MDb, Richard J. Martin, MDc, Stanley J. Szefler, MDd, David Donnell, PharmDa 
Journal of Allergy and Clinical Immunology 
Volume 106, Issue 6, Pages (December 2000)
DOI: /mai
Copyright © 2000 Mosby, Inc. Terms and Conditions

2. Fig. 1
Deposition of radiolabeled steroid after inhalation of QVAR, CFC-FP, and CFC-BDP.26
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

3. Fig. 2
Mean change in FEV1 percent predicted in patients taking 80 and 160 μg/d QVAR or HFA-placebo. (Reprinted from Hampel F, et al. J Asthma 2000;37: )
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

4. Fig. 3
Mean change in baseline in FEV1 (% of predicted normal) by week for patients receiving 80, 320, and 640 μg/d QVAR or CFC-BDP at equivalent doses. (Reprinted from Busse WW, et al. J Allergy Clin Immunol 1999;104: )
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

5. Fig. 4
Regression analysis of change from baseline at week 6 in FEV1 percent predicted (A) and FEF25%-75% (B) . (Reprinted from Busse WW, et al. J Allergy Clin Immunol 1999;104: )
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

6. Fig. 5
Proportion of patients with increasing improvement in FEV1 for 80 μg of QVAR versus equal dose of CFC-BDP. (Reprinted from Busse WW, et al. J Allergy Clin Immunol 1999;104: )
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

7. Fig. 6
Mean morning PEF (in liters per minute) in patients taking 320 μg/d QVAR or 672 μg/d CFC-BDP or HFA-placebo over 12 weeks. (Reprinted from Gross G, et al. Chest 1999;115: )
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

8. Fig. 7
Kaplan-Meier analysis showing time to onset of acute asthma episode or increased asthma symptoms. P value indicates no significant difference between the treatments. (Reprinted from Fireman P, et al. Am J Respir Crit Care Med. In press.)
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

9. Fig. 8
High-resolution computed tomography images before and after methacholine challenge at visits 2 (pretreatment baseline visit) and 4 (posttreatment visit) in a CFC-BDP–treated patient (A) and a QVARtreated patient (B) . Arrows show regions of trapped air; not all such regions have been highlighted. (Reprinted from Goldin JG, et al. J Allergy Clin Immunol 1999;104:S )
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

10. Fig. 9
Dose response of percentage suppression of morning plasma cortisol level (meta-analysis of 4 studies). (Reprinted from Lipworth BJ. Respir Med 2000;94[Suppl D]:S21-6.)
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions